Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option
Over $100M total capital raised in 2021, providing operational and strategic flexibility to execute mission to broaden patient access to innovative, safe, and efficacious non-hallucinogenic psychoplastogens for the treatment of multiple mental health disorders Delix Therapeutics, a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, announced that......